Loading
A phase 1/2 trial of Pemetrexed, Carboplatin, Etoposide, Oxaliplatin, Capecitabine and Docetaxel in advanced solid tumours, run by CStone Pharmaceuticals, now recruiting.
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06741644 by CStone Pharmaceuticals, with 800 participants planned, started 2025-02-24 and due to reach its primary completion in 2027-01. Interventions recorded: CS2009, Pemetrexed, Carboplatin, Paclitaxel, Etoposide and Nab-paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Docetaxel, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Pemetrexed, Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Etoposide, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/